Impact Therap-b (7630)の価格はいくらですか

Impact Therap-b (7630)の価格は$1.85です

Impact Therap-b (7630)の時価総額は何ですか

Impact Therap-b (7630)の時価総額は$510.85Mです

Impact Therap-b（7630）配当利回り

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

年	配当利回り	変化
提供された日付のデータは十分ではありません。

年

配当利回り

変化

提供された日付のデータは十分ではありません。

企業	配当利回り	国
Eli Lilly and Company LLY.US	0.57%	US
Johnson & Johnson JNJ.US	2.01%	US
AbbVie Inc. ABBV.US	2.74%	US
Roche Holding AG RO.SW	2.69%	CH
Merck & Co., Inc. MRK.US	2.47%	US

企業

配当利回り

国

Eli Lilly and Company

LLY.US

0.57%

Johnson & Johnson

JNJ.US

2.01%

AbbVie Inc.

ABBV.US

2.74%

Roche Holding AG

RO.SW

2.69%

Merck & Co., Inc.

MRK.US

2.47%

Impact Therap-b

7630

カテゴリー